IPTi in Mozambican Infants for Malaria Prevention
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||The Impact of Intermittent Malaria Treatment Administered Through the EPI Scheme on Malaria Morbidity in Mozambican Children|
- Incidence of first or only malaria episodes in each study cohort by 12 months of age.
- Incidence of first or only malaria episodes by group up to 12 months of age as per protocol analysis.
- Incidence of first or only malaria episodes by group up to 24 months of age.
- Incidence of multiple malaria episodes up to 12 months of age.
- Incidence of multiple malaria episodes up to 24 months of age.
- Incidence of overall and severe anaemia up to 12 months of age.
- Incidence of overall and severe anaemia up to 24 months of age.
- Proportion of humoral and cellular immune responses against malaria at 12 months of age.
- Total number of admissions and outpatient attendances up to 24 months of age.
- Prevalence of P falciparum parasitaemia and overall and severe anaemia at 12 months of age.
- Proportion of humoral responses and geometric mean antibody titres of polio, DTP and Hepatitis B at 5 months and of measles at 9 and 12 months
- Incidence of side effects in each group up to 12 months of age.
|Study Start Date:||September 2002|
|Estimated Study Completion Date:||December 2005|
The study is a randomised, double blind, placebo-controlled trial of the antimalarial drug sulphadoxine-pyrimethamine administered intermittently at 3, 4 and 9 months of age through the EPI scheme at the time of routine immunisations.
Children will be randomized into placebo and SP treatment groups by block randomization, and it is expected a similar age distribution and a similar number of children in each group.
Doses of sulphadoxine (25 mg/kg)-pyrimethamine (1.25 mg/kg) (SP) or placebo will be given by a health assistant according to bodyweight (a quarter of a tablet for those <5kg, a half for those 5-10 kg, and a whole tablet for children >10 kg). The tablets will be crashed and diluted with water for their administration.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00209794
|Centro de Investigaçao em Saude da Manhiça|
|Manhiça, Maputo, Mozambique|
|Principal Investigator:||Clara Menendez, MD, PhD||Center for International Health, Hospital Clinic de Barcelona|